Local Failure Events in Prostate Cancer Treated with Radiotherapy: A Pooled Analysis of 18 Randomized Trials from the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium (LEVIATHAN).


Journal

European urology
ISSN: 1873-7560
Titre abrégé: Eur Urol
Pays: Switzerland
ID NLM: 7512719

Informations de publication

Date de publication:
11 2022
Historique:
received: 29 03 2022
revised: 03 07 2022
accepted: 14 07 2022
pubmed: 8 8 2022
medline: 19 10 2022
entrez: 7 8 2022
Statut: ppublish

Résumé

The prognostic importance of local failure after definitive radiotherapy (RT) in National Comprehensive Cancer Network intermediate- and high-risk prostate cancer (PCa) patients remains unclear. To evaluate the prognostic impact of local failure and the kinetics of distant metastasis following RT. A pooled analysis was performed on individual patient data of 12 533 PCa (6288 high-risk and 6245 intermediate-risk) patients enrolled in 18 randomized trials (conducted between 1985 and 2015) within the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium. Multivariable Cox proportional hazard (PH) models were developed to evaluate the relationship between overall survival (OS), PCa-specific survival (PCSS), distant metastasis-free survival (DMFS), and local failure as a time-dependent covariate. Markov PH models were developed to evaluate the impact of specific transition states. The median follow-up was 11 yr. There were 795 (13%) local failure events and 1288 (21%) distant metastases for high-risk patients and 449 (7.2%) and 451 (7.2%) for intermediate-risk patients, respectively. For both groups, 81% of distant metastases developed from a clinically relapse-free state (cRF state). Local failure was significantly associated with OS (hazard ratio [HR] 1.17, 95% confidence interval [CI] 1.06-1.30), PCSS (HR 2.02, 95% CI 1.75-2.33), and DMFS (HR 1.94, 95% CI 1.75-2.15, p < 0.01 for all) in high-risk patients. Local failure was also significantly associated with DMFS (HR 1.57, 95% CI 1.36-1.81) but not with OS in intermediate-risk patients. Patients without local failure had a significantly lower HR of transitioning to a PCa-specific death state than those who had local failure (HR 0.32, 95% CI 0.21-0.50, p < 0.001). At later time points, more distant metastases emerged after a local failure event for both groups. Local failure is an independent prognosticator of OS, PCSS, and DMFS in high-risk and of DMFS in intermediate-risk PCa. Distant metastasis predominantly developed from the cRF state, underscoring the importance of addressing occult microscopic disease. However a "second wave" of distant metastases occurs subsequent to local failure events, and optimization of local control may reduce the risk of distant metastasis. Among men receiving definitive radiation therapy for high- and intermediate-risk prostate cancer, about 10% experience local recurrence, and they are at significantly increased risks of further disease progression. About 80% of patients who develop distant metastasis do not have a detectable local recurrence preceding it.

Identifiants

pubmed: 35934601
pii: S0302-2838(22)02523-4
doi: 10.1016/j.eururo.2022.07.011
pii:
doi:

Substances chimiques

Prostate-Specific Antigen EC 3.4.21.77

Types de publication

Journal Article Meta-Analysis Review Research Support, U.S. Gov't, Non-P.H.S. Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

487-498

Subventions

Organisme : Medical Research Council
ID : MC_UU_00004/02
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 12518
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C7224/A28724
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C33589/A28284
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : L30 CA231572
Pays : United States
Organisme : Cancer Research UK
ID : 7253
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2022 The Author(s). Published by Elsevier B.V. All rights reserved.

Auteurs

Ting Martin Ma (TM)

Depart of Radiation Oncology, University of California Los Angeles, Los Angeles, CA, USA.

Fang-I Chu (FI)

Depart of Radiation Oncology, University of California Los Angeles, Los Angeles, CA, USA.

Howard Sandler (H)

Department of Radiation Oncology, Cedars Sinai, Los Angeles, CA, USA.

Felix Y Feng (FY)

Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA.

Jason A Efstathiou (JA)

Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Christopher U Jones (CU)

Department of Radiation Oncology, Sutter Medical Group, Roseville, CA, USA.

Mack Roach (M)

Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA.

Seth A Rosenthal (SA)

Department of Radiation Oncology, Sutter Medical Group, Roseville, CA, USA.

Thomas Pisansky (T)

Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.

Jeff M Michalski (JM)

Department of Radiation Oncology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.

Michel Bolla (M)

Department of Radiation Therapy, CHU Grenoble, Grenoble, France.

Theo M de Reijke (TM)

Department of Urology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.

Philippe Maingon (P)

Department of Radiation Oncology, Centre Georges François Leclerc, University of Burgundy, Dijon, Burgundy, France.

Anouk Neven (A)

Luxembourg Institute of Health, Competence Center for Methodology and Statistics, Strassen, Luxembourg.

James Denham (J)

School of Medicine and Public Health, Faculty of Health and Medicine University of Newcastle, Newcastle, NSW, Australia.

Allison Steigler (A)

School of Medicine and Public Health, Faculty of Health and Medicine University of Newcastle, Newcastle, NSW, Australia.

David Joseph (D)

Department of Surgery, University of Western Australia.

Abdenour Nabid (A)

Department of Radiation Oncology, Centre Hospitaler Universitaire de Sherbrooke, Sherbrooke, QC, Canada.

Luis Souhami (L)

Department of Radiation Oncology, McGill University Health Centre, Montreal, QC, Canada.

Nathalie Carrier (N)

Centre de recherche clinique, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada.

Luca Incrocci (L)

Department of Radiation Oncology, Erasmus Medical Center, Rotterdam, The Netherlands.

Wilma Heemsbergen (W)

Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Floris J Pos (FJ)

Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Matthew R Sydes (MR)

MRC Clinical Trials Unit at UCL, University College London, London, UK.

David P Dearnaley (DP)

Academic Urology Unit, Royal Marsden Hospital, London, UK; The Institute of Cancer Research, London, UK.

Alison C Tree (AC)

The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK.

Isabel Syndikus (I)

Clatterbridge Cancer Centre, Wirral, UK.

Emma Hall (E)

The Institute of Cancer Research, London, UK.

Clare Cruickshank (C)

The Institute of Cancer Research, London, UK.

Shawn Malone (S)

The Ottawa Hospital Cancer Centre, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.

Soumyajit Roy (S)

Department of Radiation Oncology, Rush University Medical Center, Chicago, IL, USA.

Yilun Sun (Y)

Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, USA; Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA.

Nicholas G Zaorsky (NG)

Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA.

Nicholas G Nickols (NG)

Depart of Radiation Oncology, University of California Los Angeles, Los Angeles, CA, USA.

Robert E Reiter (RE)

Department of Urology, University of California Los Angeles, Los Angeles, CA, USA.

Matthew B Rettig (MB)

Department of Urology, University of California Los Angeles, Los Angeles, CA, USA; Division of Hematology/Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, CA, USA.

Michael L Steinberg (ML)

Depart of Radiation Oncology, University of California Los Angeles, Los Angeles, CA, USA.

Vishruth K Reddy (VK)

Depart of Radiation Oncology, University of California Los Angeles, Los Angeles, CA, USA.

Michael Xiang (M)

Depart of Radiation Oncology, University of California Los Angeles, Los Angeles, CA, USA.

Tahmineh Romero (T)

Department of Medicine Statistics Core, University of California Los Angeles, Los Angeles, CA, USA.

Daniel E Spratt (DE)

Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA.

Amar U Kishan (AU)

Depart of Radiation Oncology, University of California Los Angeles, Los Angeles, CA, USA. Electronic address: Aukishan@mednet.ucla.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH